Update from ALSP clinical trial

Vigil Neuroscience provide update from phase 2 of their clinical trial and natural history study for ALSP

Vigil Neuroscience reports positive interim data from phase 2 of their clinical trial evaluating treatment (VGL101) for ALSP and critical insights gained from their natural history study.

– Treatment (Iluzanebart) demonstrated favorable safety and tolerability

– Directionally supportive changes in individual patients at 6 months on MRI and NfL biomarkers

– Natural History Study continued to provide critical insights on MRI and NfL biomarkers

– Company expects to report Phase 2 IGNITE results from patients in third quarter of 2024

To read the press release: Vigil Neuro Update

Alex - The Leukodystrophy Charity